Cipher Pharmaceuticals Inc.

Total Valuation

Cipher Pharmaceuticals Inc. carries a market capitalization of 289.71M, placing it among publicly traded companies globally. Its enterprise value stands at 327.17M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Cipher Pharmaceuticals Inc. currently has 25.39M shares outstanding.

Valuation Ratios

Cipher Pharmaceuticals Inc. trades at a trailing price-to-earnings ratio of 10.79. The price-to-sales ratio is 6.54, and the price-to-book ratio stands at 2.48.

Enterprise Valuation

On an enterprise value basis, Cipher Pharmaceuticals Inc. trades at an EV/EBITDA multiple of 12.03 and an EV/FCF ratio of 10.63. The EV/Sales ratio of 6.42 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 16.37 provides insight into valuation relative to core operating earnings.

Financial Position

Cipher Pharmaceuticals Inc. maintains a current ratio of 1.25, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.32, indicating conservative leverage, while an interest coverage ratio of 533.39 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Cipher Pharmaceuticals Inc. has paid -10.64M in income taxes, reflecting an effective tax rate of 7.99.

Stock Price Statistics

Cipher Pharmaceuticals Inc.'s stock has gained approximately 24.15669% over the past 52 weeks. The 50-day moving average sits at 12.74, while the 200-day moving average is 11.43.

Income Statement

Over the trailing twelve months, Cipher Pharmaceuticals Inc. generated 50.94M in revenue and converted that into 30.87M in net income, yielding earnings per share of 1.18. EBITDA reached 27.20M, while operating income came in at 19.99M.

Balance Sheet

Cipher Pharmaceuticals Inc. holds 6.41M in cash and equivalents against 428,000.00 in total debt, resulting in a net debt position of -6.41M. Total book value stands at 134.37M, with working capital of 5.13M providing operational flexibility.

Cash Flow

Cipher Pharmaceuticals Inc. produced 30.03M in operating cash flow over the past twelve months. After subtracting -679,000.00 in capital expenditures, free cash flow totaled 29.35M - equivalent to 1.15 per share.

Margins

Cipher Pharmaceuticals Inc. operates with a gross margin of 81.63, reflecting its pricing power and cost economics. The operating margin of 39.24 and net profit margin of 60.60 provide insight into operational efficiency.

Dividends & Yields

Scores

Cipher Pharmaceuticals Inc. posts an Altman Z-Score of 13.92, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.